Gender Dysphoria (Gender Incongruence)

1. Clinical Overview

Summary

Gender Dysphoria is the clinical distress caused by a discrepancy between a person's Gender Identity (internally experienced gender) and their Sex Assigned at Birth. The condition is characterized by marked incongruence between experienced/expressed gender and assigned gender, lasting at least 6 months, and causing clinically significant distress or impairment in functioning. [1,2]

In ICD-11, the diagnosis has been reclassified from "Mental and Behavioural Disorders" to Gender Incongruence under "Conditions related to Sexual Health" to reduce stigma and recognize that the transgender identity itself is not pathological. The focus is on the distress (dysphoria) and the need for healthcare access, not on the identity as disordered. [3]

Epidemiology at a Glance

• Prevalence: Estimated 0.5-1.0% of adults identify as transgender, with increasing referrals particularly in adolescents and birth-registered females. [4,5]
• Age Distribution: Can present at any age from early childhood through adulthood; peak referrals occur during adolescence and young adulthood
• Sex Ratio: Historically MtF (male-to-female) predominated in adults (3:1), but recent cohorts show equal or reversed ratios with increasing FtM (female-to-male) presentations in youth [5]
• Comorbidity: 30-70% have co-occurring mental health conditions; autism spectrum disorder is 3-6 times more prevalent than in the general population [6,7]

Clinical Pearls

Pronouns Save Lives: Using a patient's chosen name and pronouns is the single most effective intervention a non-specialist can make. It reduces suicide risk and builds therapeutic rapport instantly. Misgendering (using incorrect pronouns) breaks trust and can re-traumatize patients.

"Binder" Safety: Trans men may use chest binders to flatten breasts. Risks include rib fractures, restricted breathing, skin breakdown, and infections. Advise: "take breaks every 8 hours"

• "never sleep in it"
• "don't buy one too small", and "stop if pain or breathlessness develops".

The "Wait" for GIC: Waiting lists for NHS Gender Identity Clinics currently exceed 2-5 years in many regions. GPs must provide interim support for mental health, monitor self-directed hormone use, and consider harm-reduction approaches under GMC guidance ("bridging prescriptions").

Safeguarding Cervical Screening: Trans men (FtM) registered with GP systems as male may be excluded from automated cervical screening recalls. Manual flag required if cervix present. Similarly, trans women need prostate monitoring regardless of gender marker.

---

2. Epidemiology

Prevalence and Incidence

Adult Population:

• Population-based surveys suggest 0.5-1.0% of adults identify as transgender or gender diverse [4]
• Dutch cohort data (1972-2015) showed steady increase: from 1:11,900 to 1:3,800 for transwomen; from 1:30,400 to 1:5,200 for transmen [5]
• Younger cohorts show higher prevalence (up to 2-3% in some adolescent samples)

Youth and Adolescent Presentations:

• Dramatic rise in referrals to gender services since 2010s, particularly in birth-registered females aged 12-17 years [8]
• UK data: Referrals to GIDS (Gender Identity Development Service) increased from ~250/year (2011) to over 5,000/year (2021) before service restructuring

Geographic Variation:

• Higher reported prevalence in urban vs. rural areas (may reflect access to services and social acceptance)
• Cross-cultural differences in presentation and terminology

Demographics

Age of Onset:

• Early Childhood Onset: Awareness of gender incongruence from ages 2-4; may express cross-gender identification during early play and language development
• Adolescent Onset: Emergence or intensification during puberty (onset of secondary sexual characteristics triggers severe distress)
• Adult Onset: Some individuals recognize and disclose gender dysphoria only in adulthood due to societal, family, or internal suppression

Sex Assigned at Birth Ratio:

• Historical data: 3:1 ratio (birth-assigned males to females) in adult clinic populations
• Recent trends: Equal or reversed ratios, with birth-assigned female adolescents now comprising majority in many youth services [5,8]

Socioeconomic and Ethnic Factors:

• No consistent association with socioeconomic status
• Under-representation of ethnic minorities in clinical samples (likely reflects systemic barriers to care rather than true prevalence differences)

Co-occurring Conditions

Mental Health Comorbidity [6,9]:

• Depression: 40-60% prevalence (higher pre-transition, decreases with gender-affirming care)
• Anxiety Disorders: 30-50%
• Autism Spectrum Disorder: 6-26% (3-6 times general population prevalence) [7]
• ADHD: Elevated rates, particularly in youth cohorts
• Eating Disorders: Increased prevalence, especially in transmasculine individuals
• Substance Use Disorders: 2-3 times higher than general population

Medical Comorbidity:

• Polycystic Ovary Syndrome (PCOS): Some evidence of higher rates in FtM individuals even pre-testosterone
• Cardiometabolic Risk: Elevated BMI, smoking rates, and metabolic syndrome prevalence

Terminology

• Cisgender: Individual whose gender identity matches sex assigned at birth
• Transgender: Umbrella term for individuals whose gender identity differs from sex assigned at birth
• Trans woman (MtF): Individual assigned male at birth who identifies as female
• Trans man (FtM): Individual assigned female at birth who identifies as male
• Non-binary/Genderqueer: Identity outside the male/female binary (may seek partial medical transition or none)
• Gender Fluid: Gender identity that varies over time
• Assigned Female at Birth (AFAB) / Assigned Male at Birth (AMAB): Preferred terminology replacing "biological sex"

---

3. Pathophysiology and Aetiology

Neurobiological Basis

Brain Structure and Function [10]:

• Neuroimaging studies show that certain sexually dimorphic brain regions in transgender individuals more closely resemble their experienced gender than assigned sex
• Bed Nucleus of the Stria Terminalis (BNSt): Post-mortem studies show size/neuron number aligns with gender identity, not assigned sex
• White Matter Microstructure: DTI studies suggest intermediate or gender-identity-congruent patterns

Hormonal Theories:

• Prenatal Androgen Exposure Hypothesis: Proposes that atypical hormone exposure during critical periods of fetal brain development may influence gender identity
• Evidence from conditions with known androgen excess (e.g., congenital adrenal hyperplasia) shows elevated but still minority rates of gender dysphoria

Genetic Factors [11]:

• Twin studies suggest heritability: Monozygotic twin concordance ~33-39%, dizygotic ~0-3%
• Candidate gene studies (CYP17, CYP19, androgen receptor genes) show inconsistent results
• Likely polygenic with multiple small-effect variants

Psychosocial and Developmental Models

NOT Caused By:

• Parenting style, childhood trauma, or "social contagion" (these are unsupported hypotheses)
• Sexual abuse (no causal relationship, though trans individuals experience higher rates of victimization)

Development of Gender Identity:

• Gender identity formation is multifactorial: biological predisposition, cognitive development, social environment
• Most children with gender-nonconforming behavior do not persist with gender dysphoria into adolescence (~12-27% persistence) [12]
• Persistence Factors: Early age of onset, intensity of dysphoria, puberty as critical period (dysphoria often intensifies or resolves during puberty)

Psychological Distress Mechanisms

The distress in gender dysphoria arises from:

1. Primary Dysphoria: Direct distress from incongruence (body parts, voice, social role)
2. Minority Stress: Societal stigma, discrimination, family rejection, violence
3. Anticipatory Anxiety: Fear of "outing", social transition challenges, medical gatekeeping

---

4. Differential Diagnosis

Key Differentials

Assessment Challenges

Gender Dysphoria vs. Body Dissatisfaction:

• Body dissatisfaction is common in adolescence; gender dysphoria is specific to gendered characteristics
• In eating disorders, body image disturbance is typically weight/shape focused, not gender-focused

Gender Dysphoria vs. Sexual Orientation:

• Gender identity (who you are) is distinct from sexual orientation (who you're attracted to)
• Trans individuals can be heterosexual, homosexual, bisexual, or asexual in relation to their gender identity

---

5. Clinical Presentation

DSM-5 Diagnostic Criteria

Gender Dysphoria in Adolescents and Adults:

A. Marked incongruence between experienced/expressed gender and assigned gender, ≥6 months, with ≥2 of:

1. Incongruence between experienced gender and primary/secondary sex characteristics
2. Strong desire to be rid of sex characteristics due to incongruence
3. Strong desire for sex characteristics of other gender
4. Strong desire to be of other gender
5. Strong desire to be treated as other gender
6. Strong conviction that one has feelings/reactions typical of other gender

B. Clinically significant distress or impairment in social, occupational, or other areas of functioning

Gender Dysphoria in Children: Requires ≥6 criteria including strong desire to be other gender and preference for cross-gender roles/toys (distinct from simple non-conformity)

Presentation by Age Group

Children (Pre-Pubertal):

• Verbalization: "I am a boy" (not just "I want to be") – stated identity, not just preference [12]
• Behavior: Strong preference for cross-gender toys, playmates, clothing
• Distress: May express hatred of genitals, wish for different anatomy
• Social: Insistence on being called by different name/pronouns
• Not Diagnostic Alone: Gender-nonconforming play is common (~2-5% children) and rarely persists

Adolescents:

• Puberty Crisis: Severe worsening at onset of menstruation, breast development, voice deepening, facial hair
• Body Dysphoria: Acute distress with developing secondary sex characteristics; may refuse to shower, look in mirrors
• Social Withdrawal: Avoidance of gendered spaces (changing rooms, bathrooms)
• Binding/Tucking: Concealment behaviors (chest binding, genital tucking)
• Mental Health: High rates of depression, self-harm, suicidality during this period

Adults:

• Presentation Variability:
  • "Early Disclosers: Consistent history from childhood, often socially transitioned or seeking medical transition"
  • "Late Disclosers: Suppressed feelings for decades; may present after life events (divorce, children leaving home, retirement)"
• Report: "I have always felt trapped in wrong body" or "I've known since childhood but couldn't act on it"
• Functional Impairment: Difficulty with relationships, employment, social participation due to dysphoria or fear of disclosure

Red Flag Presentations

Immediate Risk:

• Active suicidality with plan/intent (trans individuals have 40% lifetime suicide attempt rate pre-transition, reducing post-transition) [14]
• Self-harm directed at gendered body parts (genital mutilation, breast trauma)
• Unsafe hormone use (black market injectable estrogen/testosterone without monitoring)

Safeguarding Concerns in Youth:

• Family rejection/violence following disclosure
• Homelessness (40% of homeless youth identify as LGBTQ+)
• Sex work as survival strategy

---

6. Investigations and Assessment

Clinical Assessment (Specialist Gender Service)

Comprehensive Psychosocial Assessment:

• Gender Identity History: Onset, development, consistency, intensity of dysphoria
• Childhood and Adolescent History: Gender expression, peer relationships, family responses
• Current Gender Expression: Social transition status, name/pronoun use, passing concerns
• Dysphoria Triggers: Specific body parts, social situations, gendered interactions
• Goals of Transition: Social, medical, surgical aspirations; realistic expectations
• Mental Health: Depression, anxiety, trauma, autism, psychosis screening [6]
• Social Support: Family acceptance, peer networks, employment, housing stability
• Capacity Assessment: Understanding of interventions, risks, benefits, alternatives (critical for minors)

Diagnostic Criteria Application:

• DSM-5 or ICD-11 criteria
• Rule out differentials (BDD, psychosis, dissociative disorders)
• Assess persistence and pervasiveness

No Diagnostic "Test":

• No blood test, imaging, or genetic test diagnoses gender dysphoria
• Diagnosis is clinical, based on comprehensive assessment over multiple appointments

Baseline Investigations (Pre-Hormone Therapy)

Blood Tests [15]:

• Hormones: Testosterone, oestradiol, LH, FSH, prolactin, sex hormone-binding globulin (SHBG)
• Metabolic: Fasting glucose, HbA1c, lipid profile (baseline cardiovascular risk)
• Hepatic: LFT (baseline liver function before hormone therapy)
• Haematology: FBC (baseline for polycythaemia monitoring in testosterone users)
• Renal: U&E (electrolyte abnormalities with spironolactone use)

Other Baseline Assessments:

• Bone Density (DEXA Scan): If prolonged hypogonadism (e.g., long-term puberty blocker use) or risk factors
• Cardiovascular Risk: BP, BMI, smoking history (VTE risk stratification)
• Fertility Counselling: Mandatory discussion before hormone/surgical interventions

Differential Diagnosis Investigations

If Atypical Features:

• Karyotype: If disorders of sex development (DSD) suspected (ambiguous genitalia, delayed puberty, primary amenorrhoea)
• Imaging: Pelvic USS if PCOS or ovarian pathology suspected in FtM individuals
• Psychiatric Assessment: Formal assessment if psychosis, severe dissociation, or complex trauma

---

7. Management

Management Principles

Biopsychosocial Model:

• Gender dysphoria management is not solely medical; requires integrated mental health support, social interventions, and where appropriate, medical/surgical treatments
• Informed Consent Model (adults): After comprehensive assessment, competent adults can consent to treatment; "gatekeeping" is minimized
• Watchful Waiting vs. Affirmative Approach: Balance between premature intervention and denial of needed care (particularly contentious in youth)

Key Frameworks:

• WPATH Standards of Care v8 (2022): International gold standard, evidence-based guidelines [1]
• Endocrine Society Guidelines (2017): Hormone therapy protocols [15]
• Cass Review (2024): UK-specific recommendations for youth services, emphasizing caution and holistic care [16]

Management Algorithm

┌────────────────────────────┐
│   PRESENTATION TO GP       │
│  (Gender dysphoria concern)│
└──────────┬─────────────────┘
           │
           ▼
┌────────────────────────────┐
│  SUPPORTIVE GP CARE        │
│  • Use correct pronouns    │
│  • Mental health support   │
│  • Referral to GIC         │
│  • Interim monitoring      │
└──────────┬─────────────────┘
           │
           ▼
┌────────────────────────────┐
│  SPECIALIST ASSESSMENT     │
│  (Gender Identity Clinic)  │
│  • Psychosocial evaluation │
│  • Diagnosis confirmation  │
│  • Treatment planning      │
└──────────┬─────────────────┘
           │
     ┌─────┴─────┐
     ▼           ▼
┌────────┐  ┌────────────┐
│ SOCIAL │  │  MEDICAL   │
│TRANSI- │  │ TRANSITION │
│ TION   │  │ (Hormones) │
└────────┘  └─────┬──────┘
                  │
            ┌─────┴─────┐
            ▼           ▼
    ┌────────────┐ ┌────────────┐
    │ FEMINISING │ │MASCULINISING│
    │  (MtF)     │ │   (FtM)    │
    │ • Oestrogen│ │ •Testosterone│
    │ • Anti-    │ │            │
    │  androgens │ │            │
    └─────┬──────┘ └─────┬──────┘
          │              │
          └──────┬───────┘
                 ▼
        ┌────────────────┐
        │   SURGICAL     │
        │  TRANSITION    │
        │ • Top surgery  │
        │ • Bottom surgery│
        │ • Facial (FFS) │
        └────────────────┘

Social Transition (Non-Medical)

Components:

• Name Change: Deed poll (UK), legal name change
• Pronoun Use: He/him, she/her, they/them
• Presentation: Clothing, hairstyle, grooming aligned with gender identity
• Social Role: Living full-time in affirmed gender (at work, socially)
• Documentation: Gender marker change on passport, driving license, medical records

Real-Life Experience (RLE): Historically required 1-2 years living in gender role before hormones/surgery; now less rigid in adult care (not required for hormone initiation under informed consent models)

Medical Transition: Hormone Therapy

Feminising Hormone Therapy (MtF Transition) [15,17]

Regimen:

1. Oestrogen:

   • Oestradiol Valerate (oral): 2-6 mg daily
   • Transdermal Patches: 100-200 mcg/24h (lower VTE risk than oral)
   • Gel: 1.5-3 mg daily
   • Target: Oestradiol levels 400-600 pmol/L (pre-menopausal female range)

2. Anti-Androgens (Testosterone Suppression):

   • GnRH Analogues (e.g., Goserelin 3.6mg SC monthly): Suppresses testosterone to less than 50 ng/dL (most effective, expensive)
   • Cyproterone Acetate: 12.5-50 mg daily (risk: hepatotoxicity, prolactinoma at high doses)
   • Spironolactone: 100-300 mg daily (potassium-sparing diuretic, check U&E; risk: hyperkalaemia)
   • Finasteride: 1-5 mg daily (5-alpha reductase inhibitor; blocks DHT, prevents male-pattern baldness)

Effects (Timeline):

• 1-3 months: Decreased libido, softer skin, reduced spontaneous erections, breast budding (painful)
• 3-6 months: Breast development continues (Tanner stage 2-3), fat redistribution (hips, thighs), reduced testicular volume
• 6-12 months: Decreased muscle mass, possible decreased facial/body hair (slow, variable)
• 1-2 years: Breast development plateaus (Tanner stage 3-4, rarely 5); many require augmentation

Irreversible Effects:

• Breast development (will not regress if hormones stopped)
• Fertility loss (gradual, variable; may be permanent after prolonged use)

Monitoring [15]:

• Every 3 months (first year): Oestradiol, testosterone, LFT, prolactin
• Every 6-12 months (stable): Full hormone panel, lipids, glucose, FBC
• Cardiovascular Monitoring: BP, thromboembolic risk assessment (smoking cessation critical)

Risks and Side Effects [17]:

• Venous Thromboembolism (VTE): 2-3 fold increased risk (higher with oral oestrogen, smoking, age > 40, obesity)
• Cardiovascular Disease: Possible increased risk of MI/stroke (unclear if route-dependent)
• Osteoporosis: If inadequate oestrogen levels or prolonged GnRH analogue monotherapy
• Hyperprolactinaemia: Especially with cyproterone (screen with MRI if levels > 1000 mIU/L)
• Breast Cancer: Theoretical risk after decades of use (data limited)
• Mood Changes: Variable; some report improved mood, others emotional lability

Masculinising Hormone Therapy (FtM Transition) [15,18]

Regimen:

1. Testosterone:
   • Testosterone Enanthate/Cypionate (IM): 100-250 mg every 2 weeks, or 50-100mg weekly (smoother levels)
   • Testosterone Undecanoate (IM): 1000 mg every 10-12 weeks (long-acting)
   • Transdermal Gel: 50-100 mg daily (1-2 sachets; avoid transfer to partners/children)
   • Target: Testosterone levels 10-25 nmol/L (mid-normal male range at mid-cycle)

Effects (Timeline):

• 1-3 months: Cessation of menses (usually within 2-6 months), increased libido, clitoral enlargement (1-3 cm), oilier skin, acne
• 3-6 months: Voice deepening (irreversible), increased facial/body hair, increased muscle mass and strength
• 6-12 months: Fat redistribution (loss of hips/thighs, central gain), male-pattern scalp hair changes (recession)
• 1-2 years: Facial hair thickening (variable; may take 3-5 years for full beard), continued voice deepening

Irreversible Effects:

• Voice deepening
• Facial/body hair growth
• Clitoral enlargement
• Male-pattern baldness (if genetically predisposed)
• Fertility impairment (may be permanent)

Monitoring [15]:

• Every 3 months (first year): Testosterone (trough and peak if injectable), FBC (polycythaemia), LFT
• Every 6-12 months (stable): Full hormone panel, lipids, HbA1c, FBC, cervical screening if cervix present
• Bone Density: Baseline if risk factors, repeat every 2-5 years

Risks and Side Effects [18]:

• Polycythaemia (Erythrocytosis): 5-20% develop Hct > 50% (increased stroke/MI risk; may require dose reduction or venesection)
• Cardiovascular Disease: Possible increased risk (lipid changes, weight gain, smoking synergy)
• Hepatotoxicity: Rare, but monitor LFT (especially oral testosterone, now rarely used)
• Acne and Androgenic Alopecia: Common; treat with topical retinoids, anti-androgens (finasteride), or dose adjustment
• Vaginal Atrophy: Dryness, bleeding, increased infection risk (topical oestrogen cream can help without systemic feminisation)
• Ovarian Changes: Possible increased risk of PCOS-like changes (multifollicular ovaries); cancer risk unclear
• Mood Changes: Increased irritability or mood swings in some; others report improved mood

Contraindications to Hormone Therapy:

• Absolute: Active or recent VTE (for oestrogen), pregnancy, oestrogen-sensitive cancer (MtF), uncontrolled polycythaemia (FtM)
• Relative: Cardiovascular disease (require specialist input), severe liver disease, prolactinoma

Fertility Preservation

Critical Counselling Point [1]:

• Hormone therapy and surgical interventions will impair or eliminate fertility
• Must be discussed before treatment initiation

Options:

• MtF Individuals: Sperm cryopreservation (prior to oestrogen/anti-androgens)
• FtM Individuals: Oocyte or embryo cryopreservation (prior to testosterone)
• Cost: Self-funded in most countries (NHS England now offers some coverage)

Barriers:

• Financial cost (£500-£3000+)
• Dysphoria triggered by genital use (sperm collection, oocyte retrieval requires stopping hormones temporarily)
• Adolescents: Puberty blockers preserve fertility potential, but cross-sex hormones impair it

Surgical Interventions

Chest Surgery ("Top Surgery"):

• FtM: Bilateral mastectomy with male chest contouring (high satisfaction, low regret)
• MtF: Breast augmentation (if hormone-induced breast growth inadequate, usually Tanner 3-4 max)

Genital Surgery ("Bottom Surgery"):

• MtF (Vaginoplasty):

  • Penile inversion or sigmoid colon vaginoplasty
  • Creation of neovagina, clitoris (from glans), labia
  • Requires lifelong dilation to maintain vaginal depth
  • "Complications: Stenosis, fistula (rectovaginal, urethrovaginal), loss of sensation, unsatisfactory aesthetics"

• FtM (Phalloplasty or Metoidioplasty):

  • "Metoidioplasty: Release of testosterone-enlarged clitoris to create small phallus (3-5 cm); can achieve erection without prosthesis; can stand to urinate"
  • "Phalloplasty: Construction of phallus from forearm/thigh flap (12-18 cm); requires erectile prosthesis; multiple stages"
  • "Scrotoplasty: Creation of scrotum with testicular prostheses"
  • "Complications: Urethral stricture/fistula (30-50% for phalloplasty), flap loss, unsatisfactory aesthetics, loss of sensation"

Facial Surgery:

• Facial Feminization Surgery (FFS): Forehead contouring, rhinoplasty, jaw/chin reshaping, tracheal shave (Adam's apple reduction) [19]
• Voice Surgery (Feminization): Less common (logopedic therapy preferred); pitch-raising procedures (cricothyroid approximation)

Hysterectomy and Oophorectomy (FtM):

• Removal of uterus/ovaries after prolonged testosterone (reduces dysphoria, eliminates menstruation risk, reduces hormone monitoring needs)
• Allows testosterone dose reduction (no endogenous oestrogen to suppress)

Orchiectomy (MtF):

• Removal of testes allows discontinuation of anti-androgens, reduces oestrogen dose needed

Timing:

• Most surgeons require ≥12 months continuous hormone therapy before genital surgery (to ensure informed decision and allow reversible changes to occur first)
• Two letters of recommendation from mental health professionals (historical "gatekeeping"; now streamlined in many centres)

Voice and Communication Therapy

• MtF: Speech and language therapy to raise pitch, modify resonance, intonation, non-verbal communication (no reliable surgical option)
• FtM: Testosterone deepens voice (usually no therapy needed); communication style coaching available

Management in Children and Adolescents [16]

Evolution of Approach:

• Historical: Psychotherapy to align identity with assigned sex ("conversion therapy") – now recognized as harmful and unethical
• 2000s-2020: "Gender-affirmative" model: Puberty blockers → cross-sex hormones if persistent
• Current (Post-Cass Review, 2024): Shift to "holistic exploration" and caution, especially for adolescents with late-onset or rapid-onset dysphoria

Cass Review (2024) Key Findings [16]:

• Weak evidence base for medical interventions in youth (puberty blockers, hormones)
• Long-term outcomes (bone density, fertility, psychosocial) insufficiently studied
• High rates of autism and mental health comorbidity require comprehensive assessment
• Recommendation: Puberty blockers only in research context; holistic psychosocial support prioritized

Puberty Blockers (GnRH Analogues):

• Mechanism: Pause endogenous puberty (reversible if stopped)
• Rationale: Provides time for exploration, reduces distress from unwanted pubertal changes, improves surgical outcomes if transition pursued
• Current Status (UK): Not routinely prescribed outside clinical trials (as of 2024)
• Concerns: Bone density impact, unknown cognitive/psychosocial effects, pathway to near-100% progression to cross-sex hormones in research cohorts

Cross-Sex Hormones in Adolescents:

• Previously initiated age 16+ (some centres age 14+)
• Now more restrictive: Cass Review recommends extreme caution less than 18 years
• Requires multidisciplinary team assessment, clear persistent dysphoria, mental health stability, family support

Psychosocial Support (Preferred Approach):

• Mental health therapy (NOT conversion therapy; exploratory, non-directive)
• Peer support groups
• Family therapy (addressing acceptance, adjustment)
• School support (name/pronoun use, bathroom access, bullying prevention)
• Management of comorbid autism, ADHD, trauma, depression

Role of the GP (Non-Specialist)

Supportive Care:

1. Respectful Communication: Use chosen name/pronouns; update systems (flag automatic screening exclusions)
2. Mental Health Support: Prescribe antidepressants/anxiolytics as indicated; refer to CAMHS/adult psychiatry
3. Referral to Gender Services: Initiate referral to GIC (expect 2-5 year wait; manage expectations)
4. Interim Monitoring: If patient self-medicating (buying hormones online), offer harm reduction:
   • Baseline bloods (hormones, LFT, FBC, lipids)
   • Regular monitoring (every 3-6 months)
   • VTE risk counselling (smoking cessation, avoid oestrogen if high risk)
5. Shared Care Prescribing: Once initiated by specialist, GP can prescribe under shared care agreement (not all CCGs/ICBs fund)
6. General Health Screening: Cervical screening (FtM with cervix), prostate monitoring (MtF), cardiovascular risk

"Bridging Prescriptions":

• GMC guidance allows GP prescribing before specialist assessment in exceptional circumstances:
  • Patient already self-medicating with black market hormones (harm reduction)
  • High suicide risk linked to lack of access
  • Requires documentation, specialist advice sought, informed consent, monitoring protocol
• Controversial and medicolegally complex; not routine practice

---

8. Complications and Adverse Effects

Mental Health Complications

Pre-Transition:

• Suicidality: 40% lifetime suicide attempt rate in some cohorts (pre-transition) [14]
• Depression and Anxiety: Prevalence 40-70%; often improves post-transition
• Substance Misuse: Higher rates of alcohol, cannabis, non-prescribed hormone use
• Social Isolation: Family rejection, peer bullying, employment discrimination

Post-Transition:

• Mental health generally improves with gender-affirming care [9,20]
• Persistent mental health issues if comorbid conditions untreated or ongoing minority stress
• Regret/Detransition: Low rates (1-5%) but require sensitive support; often driven by social factors (family rejection, discrimination) rather than misdiagnosis

Medical Complications of Hormone Therapy

MtF Hormones:

• VTE: 2-3 fold increased risk [17]
• Cardiovascular Events: Possible increased MI/stroke risk
• Osteoporosis: If inadequate oestrogen dosing
• Breast Cancer: Theoretical long-term risk (data limited, no clear increase in available studies)
• Prolactinoma: With high-dose cyproterone acetate

FtM Hormones:

• Polycythaemia: 5-20% develop elevated haematocrit (requires dose adjustment or venesection) [18]
• Cardiovascular Events: Possible increased risk (lipid changes, hypertension)
• Liver Dysfunction: Elevated transaminases (usually mild)
• Vaginal Atrophy: Bleeding, pain, infection risk
• Ovarian Cancer: No clear increased risk, but long-term data limited

Surgical Complications

General Surgical Risks:

• Infection, bleeding, poor wound healing, anaesthetic complications
• Unsatisfactory aesthetic outcomes (requires revision surgery)

Specific to Genital Surgery:

• Vaginoplasty: Vaginal stenosis (requires lifelong dilation), fistula (recto-vaginal, urethro-vaginal), urinary retention, loss of sexual sensation
• Phalloplasty: Urethral stricture/fistula (30-50%), flap necrosis, erectile prosthesis complications
• Hysterectomy/Oophorectomy: Surgical menopause (if ovaries removed; requires testosterone continuation to prevent osteoporosis)

---

9. Prognosis and Outcomes

Outcomes of Gender-Affirming Treatment

Mental Health Improvements [9,20]:

• Systematic reviews show significant reductions in depression, anxiety, and suicidality following gender-affirming hormone therapy
• Quality of life improves across multiple domains
• Social support and family acceptance are strongest predictors of positive outcomes

Satisfaction with Transition:

• Hormone Therapy: High satisfaction (> 85% in most studies)
• Surgical Outcomes: Generally high satisfaction, particularly for chest surgery (FtM mastectomy ~95% satisfaction) [20]
• Genital Surgery: Satisfaction 80-90%, though complication rates are significant (30-50% require revision)

Regret and Detransition [5]:

• Low rates: ~1-5% in longitudinal cohorts
• Reasons for Detransition:
  • Social factors (family rejection, employment discrimination, safety concerns) – most common
  • Misdiagnosis or evolving gender identity – less common
  • Medical complications
• Support for Detransitioners: Important and often neglected; requires non-judgmental care

Long-Term Health Considerations

Cardiovascular Health:

• Long-term cardiovascular risk unclear; cross-sex hormones alter lipid profiles, blood pressure
• Smoking cessation, weight management, regular monitoring critical

Bone Health:

• Risk of osteoporosis if prolonged hypogonadism (inadequate hormone dosing, puberty blocker use without timely sex hormone initiation)
• DEXA screening recommended for at-risk individuals

Cancer Screening:

• Cervical Screening: FtM individuals with cervix require screening (often missed by automated systems)
• Prostate Screening: MtF individuals may have reduced PSA due to anti-androgens; maintain vigilance
• Breast Cancer: Both MtF (due to oestrogen) and FtM (residual breast tissue) require screening

---

10. Evidence and Guidelines

Key International Guidelines

Landmark Evidence

WPATH Standards of Care v8 (2022) [1]:

• International consensus from multidisciplinary experts
• Recognizes gender diversity beyond binary
• Emphasizes individualized care, informed consent, reduction of gatekeeping for adults
• Addresses youth care with attention to neurodiversity, mental health comorbidity

The Cass Review (2024) [16]:

• Independent review of UK paediatric gender services
• Findings: Weak evidence for medical interventions in youth, high rates of comorbidity, need for holistic approach
• Impact: Restricted puberty blocker use to research settings; restructured UK youth services

Amsterdam Cohort (2018) [5]:

• Longitudinal data 1972-2015: Increasing prevalence, very low regret rates (~0.6%)
• Shift in sex ratio (more AFAB presentations in recent cohorts)

Mental Health Outcomes Meta-Analysis (2022) [9]:

• Systematic review: Gender-affirming care associated with significant improvements in mental health, particularly depression and anxiety
• Effect sizes moderate to large

Puberty Blocker Studies [22]:

• Limited high-quality evidence; small sample sizes, short follow-up
• Concerns re: bone density, cognitive development, progression to cross-sex hormones
• NICE (2020) assessment: "Low-quality evidence"

---

11. Practical Scenarios and Exam Focus

Common Exam Questions

1. "Trans man presents with pelvic pain. What must you consider?"

• Answer: Remember trans men (FtM) may retain uterus/ovaries despite testosterone use
  • "Differential: Pregnancy (if sexually active with partners who produce sperm), ovarian cyst/torsion, endometrial atrophy/bleeding, pelvic inflammatory disease, ovarian cancer"
  • "Action: Pregnancy test, pelvic examination (sensitive approach; offer chaperone, discuss dysphoria triggers), pelvic ultrasound, STI screening"

2. "A 25-year-old trans woman requests hormone therapy. What are the contraindications?"

• Answer:
  • "Absolute: Active/recent VTE, oestrogen-sensitive cancer (breast, endometrial if uterus retained), pregnancy"
  • "Relative: Cardiovascular disease (MI, stroke, uncontrolled hypertension), heavy smoking (> 10/day), age > 40 with other risk factors, severe liver disease, hyperprolactinaemia/prolactinoma"
  • "Action: Risk assessment, consider transdermal oestrogen (lower VTE risk), smoking cessation, specialist input if relative contraindications"

3. "How do you monitor testosterone therapy in a trans man?"

• Answer:
  • "Hormone Levels: Testosterone (trough for IM injections = just before next dose; target 10-25 nmol/L)"
  • "FBC: Haematocrit/Hb (polycythaemia risk; if Hct > 50%, reduce dose or venesect)"
  • "Lipids and HbA1c: Cardiovascular risk (testosterone may worsen lipids, increase weight)"
  • "LFT: Monitor hepatotoxicity (rare)"
  • "Cervical Screening: If cervix present (manual recall; automated systems miss trans men registered as male)"
  • "Frequency: Every 3 months first year, every 6-12 months when stable"

4. "Can a GP start hormone therapy for gender dysphoria?"

• Answer:
  • "General Rule: No. Specialist initiation by Gender Identity Clinic recommended"
  • "Exceptions (Bridging Prescriptions): GMC allows GP to prescribe before specialist in specific harm reduction cases:"
    • Patient already self-medicating with black market hormones (high risk of improper dosing, no monitoring)
    • Significant suicide risk linked to lack of access
    • Requirements: Document decision, seek specialist advice (phone call to GIC), obtain informed consent, establish monitoring protocol, review regularly
  • "Shared Care: Once initiated by specialist, GP can prescribe under shared care agreement (if commissioned by local ICB)"

5. "What is the role of the Cass Review in UK gender services?"

• Answer:
  • Independent review (2024) of children and young people's gender identity services in England
  • "Key Findings: Weak evidence base for puberty blockers/hormones in youth; high rates of comorbid autism/mental health issues; need for holistic, individualized care"
  • "Recommendations: Puberty blockers only in research settings; comprehensive psychosocial assessment prioritized; caution with medical interventions less than 18 years"
  • Impact: NHS England restructured paediatric gender services; shift from "affirmative" to "exploratory" model

6. "A 16-year-old requests puberty blockers. What is the current UK approach?"

• Answer (Post-Cass Review):
  • Puberty blockers (GnRH analogues) not routinely prescribed outside of clinical research trials
  • "Rationale: Insufficient evidence on long-term bone health, cognitive development, psychosocial outcomes; concern re: near-universal progression to cross-sex hormones"
  • "Current Approach: Holistic psychosocial support, mental health treatment, social transition if appropriate, family therapy"
  • "Exceptions: May be considered in exceptional cases (severe, persistent dysphoria with significant suicide risk) with multidisciplinary team approval and research protocol enrolment"

Viva Voce Talking Points

Topic: "Discuss the management of gender dysphoria in adults."

• Open with Principles: Biopsychosocial approach; not all individuals require/desire medical intervention; informed consent for competent adults
• Pathway: Social transition → hormone therapy (if desired) → surgical interventions (if desired)
• Hormone Details: Feminising (oestrogen + anti-androgens) vs. masculinising (testosterone); effects timeline, monitoring, risks
• Surgical Options: Chest, genital, facial surgery; highlight satisfaction rates and complication profiles
• Holistic Care: Mental health support, fertility counselling, cardiovascular risk management
• Controversies: Detransition (low rates, need supportive care); access barriers (long waiting lists, funding); medicolegal issues (bridging prescriptions)

Topic: "Explain the Cass Review and its implications."

• Background: Independent review of UK paediatric gender services (2024) led by Dr. Hilary Cass
• Motivations: Rapid rise in referrals (especially AFAB youth), concerns about evidence base, high comorbidity rates
• Key Findings:
  1. Weak evidence for puberty blockers/hormones (bone, fertility, psychosocial outcomes unknown)
  2. High rates of autism (6-26% vs. ~1% general population), mental health issues
  3. Pathway was too linear (blockers → hormones); insufficient exploration of comorbidity
• Recommendations: Holistic psychosocial care; puberty blockers only in research; caution with hormones less than 18; treat comorbidities first
• Controversy: Polarized responses; trans advocacy groups concerned about access barriers; clinicians divided on evidence interpretation
• Impact: NHS England restructured services; some view as necessary recalibration, others as restriction of rights

---

12. Patient and Layperson Explanation

What is Gender Dysphoria?

Gender dysphoria is the distressing feeling that your gender identity (who you know yourself to be inside) doesn't match your sex assigned at birth (based on physical anatomy). For example, you may have been assigned male at birth but know yourself to be female, or vice versa.

Is it a mental illness?

No. Being transgender is a natural variation of human diversity, not an illness. The "diagnosis" of gender dysphoria exists so that:

1. Healthcare systems can recognize and treat the distress it causes
2. You can access transition-related care (hormones, surgery) through medical services

In fact, recent medical classifications (like ICD-11) moved gender dysphoria out of the "mental illness" category to reduce stigma.

What causes it?

The causes are complex and not fully understood. Research suggests:

• Biological factors: Brain development, hormone exposure before birth, genetics
• NOT caused by: Parenting, trauma, or "social influence"

What is transitioning?

Transitioning is the process of living as your true gender. It can involve:

1. Social Transition (no medical treatment):

   • Changing your name and pronouns
   • Dressing and presenting as your gender
   • Asking others to treat you as your gender

2. Medical Transition:

   • Hormone Therapy: Taking medications to change your body (develop breasts, deepen voice, grow facial hair, etc.)
   • Not everyone wants or needs medical transition

3. Surgical Transition:

   • Operations to alter physical characteristics (chest, genitals, face)
   • Not everyone pursues surgery; it's a personal choice

What are the risks?

Mental Health Risks (if untreated):

• Gender dysphoria is associated with high rates of depression, anxiety, and suicidality, often due to the distress of living in the "wrong" body and societal discrimination

Medical Treatment Risks:

• Hormones: Blood clots (oestrogen), high red blood cell count (testosterone), cardiovascular risks
• Surgery: Complications like infection, unsatisfactory results, loss of fertility
• Importance of monitoring: Regular blood tests and doctor visits are essential

Where can I get help?

1. Talk to your GP: They can refer you to a specialist Gender Identity Clinic (GIC)
2. Expect a wait: NHS waiting lists are currently 2-5 years in many areas
3. Get support while waiting:
   • Mental health services (counselling, therapy)
   • Support groups (Mermaids for youth, Gendered Intelligence, local LGBTQ+ groups)
   • Helplines: Switchboard LGBT+ (0300 330 0630), Samaritans (116 123)

What will happen at the Gender Clinic?

• Assessment: Several appointments with specialists (psychiatrists, psychologists) to understand your history, feelings, and goals
• Diagnosis: Confirming gender dysphoria (not everyone who is gender-nonconforming has dysphoria requiring treatment)
• Treatment Planning: Discussing options (social transition, hormones, surgery) based on your needs and goals

What about children and teenagers?

This is an area of active debate and changing practice:

• Social transition (name, pronouns, clothing) can be explored at any age
• Medical treatments (puberty blockers, hormones) are now approached with more caution in the UK following the Cass Review (2024)
• Current approach: Holistic support focusing on mental health, family, and exploration before medical interventions

Will my life improve?

• Research shows: Most people who transition experience significant improvements in mental health and quality of life
• Success factors: Family support, access to care, safe social environment
• Regret is rare: About 1-5% of people who transition later detransition, often due to social pressures rather than regret about their identity

---

13. References

Primary Evidence-Based Sources

1. Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health. 2022;23(Suppl 1):S1-S259. doi:10.1080/26895269.2022.2100644. PMID: 36238954

2. Ristori J, Steensma TD. Gender dysphoria in childhood. Int Rev Psychiatry. 2016;28(1):13-20. doi:10.3109/09540261.2015.1115754. PMID: 26754056

3. Reed GM, Drescher J, Krueger RB, et al. Disorders related to sexuality and gender identity in the ICD-11: revising the ICD-10 classification based on current scientific evidence, best clinical practices, and human rights considerations. World Psychiatry. 2016;15(3):205-221.

4. Zucker KJ. Epidemiology of gender dysphoria and transgender identity. Sex Health. 2017;14(5):404-411. doi:10.1071/SH17067. PMID: 28838353

5. Wiepjes CM, Nota NM, de Blok CJM, et al. The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets. J Sex Med. 2018;15(4):582-590. doi:10.1016/j.jsxm.2018.01.016. PMID: 29463477

6. Kallitsounaki A, Williams DM. Autism Spectrum Disorder and Gender Dysphoria/Incongruence. A systematic Literature Review and Meta-Analysis. J Autism Dev Disord. 2023;53(8):3103-3117. doi:10.1007/s10803-022-05517-y. PMID: 35596023

7. Lai MC, Kassee C, Besney R, et al. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):819-829. doi:10.1016/S2215-0366(19)30289-5. PMID: 31447415

8. Miroshnychenko A, Ibrahim S, Roldan Y, et al. Gender affirming hormone therapy for individuals with gender dysphoria aged less than 26 years: a systematic review and meta-analysis. Arch Dis Child. 2025;110(5):archdischild-2024-327921. doi:10.1136/archdischild-2024-327921. PMID: 39855725

9. Costa R, Colizzi M. The effect of cross-sex hormonal treatment on gender dysphoria individuals' mental health: a systematic review. Neuropsychiatr Dis Treat. 2016;12:1953-1966. doi:10.2147/NDT.S95310. PMID: 27536118

10. T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of Transgender Medicine. Endocr Rev. 2019;40(1):97-117. doi:10.1210/er.2018-00011. PMID: 30307546

11. Theisen JG, Sundaram V, Filchak MS, et al. The use of whole exome sequencing in a cohort of transgender individuals to identify rare genetic variants. Mol Genet Genomic Med. 2019;7(4):e00550.

12. Steensma TD, McGuire JK, Kreukels BP, Beekman AJ, Cohen-Kettenis PT. Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study. J Am Acad Child Adolesc Psychiatry. 2013;52(6):582-590.

13. Soldati L, Hasler R, Recordon N, et al. Gender Dysphoria and Dissociative Identity Disorder: A Case Report and Review of Literature. Sex Med. 2022;10(5):100553. doi:10.1016/j.esxm.2022.100553. PMID: 35998393

14. Tordoff DM, Wanta JW, Collin A, et al. Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care. JAMA Netw Open. 2022;5(2):e220978. doi:10.1001/jamanetworkopen.2022.0978. PMID: 35212746

15. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903. doi:10.1210/jc.2017-01658. PMID: 28945902

16. Cass H. The Cass Review: Independent review of gender identity services for children and young people. 2024. Available at: https://cass.independent-review.uk/

17. Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017;5(4):291-300. doi:10.1016/S2213-8587(16)30319-9. PMID: 27916515

18. Chew D, Anderson J, Williams K, May T, Pang K. Hormonal Treatment in Young People With Gender Dysphoria: A Systematic Review. Pediatrics. 2018;141(4):e20173742. doi:10.1542/peds.2017-3742. PMID: 29514975

19. Coon D, Berli J, Oles N, et al. Facial Gender Surgery: Systematic Review and Evidence-Based Consensus Guidelines from the International Facial Gender Symposium. Plast Reconstr Surg. 2022;149(1):102e-119e. doi:10.1097/PRS.0000000000008668. PMID: 34936625

20. Ireland K, Hughes M, Dean NR. Do hormones and surgery improve the health of adults with gender incongruence? A systematic review of patient reported outcomes. ANZ J Surg. 2025;95(5):1009-1016. doi:10.1111/ans.70028. PMID: 39973516

21. NHS England. Service Specification: Gender Identity Services for Adults (Non-Surgical Interventions). 2019.

22. Taylor J, Mitchell A, Hall R, et al. Interventions to suppress puberty in adolescents experiencing gender dysphoria or incongruence: a systematic review. Arch Dis Child. 2024;109(11):899-909. doi:10.1136/archdischild-2023-326669. PMID: 38594047

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with qualified healthcare professionals. Gender dysphoria management requires specialist input; this resource provides an overview for learning and should not replace formal clinical guidelines or individualized care plans.